Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castration Sensitive Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT02723526
What this trial is testing

Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Fudan University 100
Large-scale testing (Phase 3)UnknownNCT03879122
What this trial is testing

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Spanish Oncology Genito-Urinary Group 135
Large-scale testing (Phase 3)Active Not RecruitingNCT04493853
What this trial is testing

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Who this might be right for
Hormone-Sensitive Prostate Cancer
AstraZeneca 1,012
Not applicableActive Not RecruitingNCT06010914
What this trial is testing

Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Bayer 100
Testing effectiveness (Phase 2)Ended earlyNCT03649841
What this trial is testing

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Who this might be right for
Castration-Sensitive Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Prostate Carcinoma+5 more
University of Washington 10
Testing effectiveness (Phase 2)Study completedNCT02020070
What this trial is testing

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT03361735
What this trial is testing

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Adenocarcinoma
City of Hope Medical Center 25
Large-scale testing (Phase 3)Study completedNCT02677896
What this trial is testing

Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 1,150
Not applicableTemporarily pausedNCT07146113
What this trial is testing

Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation

Who this might be right for
Prostate Cancer
AstraZeneca 400
Testing effectiveness (Phase 2)UnknownNCT05717660
What this trial is testing

APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer

Who this might be right for
Oligometastatic Hormone Sensitive Prostate Cancer
Azienda Ospedaliero-Universitaria Careggi 180
Not applicableNot Yet RecruitingNCT07806591
What this trial is testing

Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in India

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Bayer 50
Large-scale testing (Phase 3)Looking for participantsNCT07333066
What this trial is testing

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD 320
Not applicableLooking for participantsNCT04612907
What this trial is testing

Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer

Who this might be right for
Prostate CancerRadiotherapy Side EffectMetastatic Cancer
Umeå University 420
Large-scale testing (Phase 3)Study completedNCT04191096
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 1,251
Testing effectiveness (Phase 2)Study completedNCT04443062
What this trial is testing

Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Radboud University Medical Center 58
Large-scale testing (Phase 3)Active Not RecruitingNCT02489318
What this trial is testing

Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

Who this might be right for
Prostate Cancer
Aragon Pharmaceuticals, Inc. 1,052
Not applicableLooking for participantsNCT07691697
What this trial is testing

PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer

Who this might be right for
Oligoprogressive Prostate CancerMetastatic Prostate Cancer
Affidea Nu-med Center of Oncological DIagnostics and Therapy 1,000
Large-scale testing (Phase 3)Active Not RecruitingNCT04076059
What this trial is testing

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone Sensitive Prostate Cancer
Astellas (Beijing) Pharmaceutical R&D Co., Ltd. 180
Not applicableLooking for participantsNCT06835218
What this trial is testing

PROCARE - PROstate Cancer Real World Evidence Registry

Who this might be right for
Prostate CancerBiochemical Recurrence of Malignant Neoplasm of ProstateNon-metastatic Castration-resistant Prostate Cancer+2 more
UroTrials Company (GmbH) 5,000
Not applicableActive Not RecruitingNCT06874114
What this trial is testing

An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 700
Next Page